Skip to main content
🧬Peptide Protocol Wiki

Melanotan-2: Research & Studies

Scientific evidence, clinical trials, and research findings

Evidence Level: low
✓Reviewed byDr. Research Team(MD (composite credential representing medical review team), PhD in Pharmacology)
📅Updated February 1, 2026
Verified

📌TL;DR

  • •3 clinical studies cited
  • •Overall evidence level: low
  • •5 research gaps identified
Evidence pyramid for Melanotan-2 research
Overview of evidence quality and study types

Research Studies

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study

Dorr RT, Lines R, Levine N, et al. (1996) • Life Sciences

PubMedDOI
RCTn=3Phase 1

First-in-human phase I pilot study evaluating safety and melanotropic effects of MT-II in healthy male volunteers

Key Findings

  • Single-blind placebo-controlled trial in 3 normal male volunteers
  • Subcutaneous doses escalated from 0.01 to 0.03 mg/kg
  • Demonstrated melanotropic activity with manageable side effects

Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction

Wessells H, Fuciarelli K, Hansen J, et al. (1998) • Journal of Urology

PubMedDOI
RCTn=10Phase 2

Double-blind placebo-controlled crossover study showing MT-II 0.025 mg/kg SC initiated erections in 8/10 men with psychogenic ED

Key Findings

  • Mean tip rigidity >80% duration: 38 min (MT-II) vs 3 min (placebo, P=0.0045)
  • Side effects: nausea, stretching, yawning, decreased appetite
  • Erections occurred without visual sexual stimulation

Melanocortin receptor agonists, penile erection, and sexual motivation - human studies with Melanotan II

Wessells H, Levine N, Hadley ME, et al. (2000) • International Journal of Impotence Research

PubMedDOI
RCTn=20Phase 2

Combined analysis of human MT-II studies showing erections in 17/20 men and increased sexual desire

Key Findings

  • 17/20 men had erection after at least one MT-II injection without visual stimulation
  • Mean 41 min tip rigidity >80%
  • Increased sexual desire: 68% of MT-II doses vs 19% of placebo (P<0.01)
  • Nausea was dose-limiting; 12.9% had severe nausea at 0.025 mg/kg

Unlock full research citations

Free access to all clinical studies, citations, and evidence summaries.

150+ peptide profiles ¡ 30+ comparisons ¡ 18 research tools

Already subscribed?
Research timeline for Melanotan-2
Key studies and discoveries over time

Community Experience Data

See how community outcomes align with (or diverge from) the research findings above.

Based on 500+ community reports

View community protocols

Explore research gaps across all peptides → | View clinical trial pipeline →

🔍Research Gaps & Future Directions

  • •No adequately powered multicenter RCTs for any indication
  • •Human PK/PD parameters (Cmax, Tmax, AUC, clearance) not reported in clinical studies
  • •Long-term safety data limited to case reports from unregulated use
  • •Systematic product quality characterization of online-sourced MT-II lacking
  • •Formal dose-optimization studies in humans not conducted

Research Overview#

The research literature on Melanotan-2 spans hundreds of preclinical studies across multiple therapeutic areas. Below is a structured review of the key studies, systematic reviews, and identified research gaps.

Key Preclinical Studies#

Why these are the most important/highly cited

  • These four publications constitute the foundational human MT‑II clinical evidence base cited across multiple peer‑reviewed reviews, with the IJIR 2000 report alone accruing over 100 citations and the Life Sciences 1996 pilot repeatedly referenced as the first‑in‑human evaluation. Their consistent reporting of robust erectogenic effects, balanced by notable adverse effects (especially nausea) and long onset time, established the therapeutic signal and the limitations that redirected development toward related molecules (e.g., intranasal bremelanotide).

Gastrointestinal Research#

• Cardiovascular and gastrointestinal safety characterization: Nausea is frequent in MT‑2 erectile‑dysfunction studies; class analogs demonstrate small but measurable transient BP increases and HR changes under controlled monitoring, indicating the need for standardized hemodynamic assessment in MT‑2 trials.

• Outcome measurement and phenotyping: Early efficacy studies used limited baseline characterization and potentially biased outcome measures (e.g., single‑night NPT, device‑induced stimulation), and provided minimal dermatologic phenotyping beyond self‑report, constraining interpretability.

• Mechanistic uncertainty for melanoma risk: Case reports and reviews raise plausible immune‑modulatory mechanisms (e.g., α‑MSH anti‑inflammatory effects, altered immune–tumor interaction) but evidence is conflicting and largely preclinical; there are no translational human biomarker studies under clinically relevant MT‑2 exposure.

• Public‑health surveillance: Despite widespread unregulated use and online markets, there are limited population‑level data on prevalence, patterns, and harms; evidence derives from descriptive or qualitative reports.

• Phase I/II PK/PD and dose‑finding: Single‑ and multiple‑ascending‑dose trials of GMP‑grade MT‑2 to define PK (AUC, Cmax, t1/2), PD (melanin density, validated sexual‑function metrics), dose–response, and acute AE profile, with standardized hemodynamic monitoring.

• Adequately powered randomized controlled trials: Multicenter RCTs for specific indications (e.g., ED adjunct, photoprotection) with robust baseline phenotyping, validated outcomes, and systematic safety capture (nausea, BP/HR, dermatologic changes), and follow‑up ≥6–12 months.

• Longitudinal safety cohorts/registries: Prospective cohorts of MT‑2 users (regulated and unregulated) with standardized dermatologic exams, dermoscopy, and linkage to cancer registries to quantify risks of new/changing nevi and melanoma over years.

• Forensic/analytical characterization of market products: Systematic sampling of internet‑sourced MT‑2 for identity, purity, potency, and contaminants using LC–MS/MS and stability testing to inform both research sourcing and regulatory guidance.

• Mechanistic translational studies: Controlled human and animal studies to probe melanocortin–immune–tumor pathways under clinically relevant dosing (e.g., immune cell profiling, DNA‑repair metrics, oxidative stress), clarifying whether MT‑2 alters melanoma initiation/progression risk.

• Public‑health surveillance and harm‑reduction research: Population surveys and sentinel surveillance to estimate prevalence and patterns of MT‑2 use, adverse events, and evaluate messaging/interventions that reduce harm in settings of ongoing unregulated access.

Embedded summary table

Gap/limitation themeWhat the literature shows (1–2 sentences)Key methodological issuesRepresentative sourcesPriority studies needed
1. Paucity of randomized controlled trials and small samplesHuman MT‑II data are limited to small, early volunteer trials and crossover studies showing short‑term signals for efficacy (erection, tanning) but...Small n, single‑dose/short‑term designs, lack of multicenter RCTs and inadequate statistical power.Wessells et al., 2000; Evans et al. (evansUnknownyearauthorsandeditor pages 155-155)Large, randomized, placebo‑controlled trials (parallel or crossover) with adequate sample sizes; endpoints: efficacy (validated scales), safety, an...
2. Absent human PK/PD and dose–response dataAuthors repeatedly note lack of human pharmacokinetic/pharmacodynamic characterization limiting interpretation of onset, duration and dose relation...No standardized PK sampling, limited dose‑escalation studies, and extrapolation from animal PK.Wessells et al., 2000; Evans et al. (evansUnknownyearauthorsandeditor pages 155-155)Phase I PK/PD and dose‑finding studies in humans (single and multiple ascending doses); endpoints: plasma PK, receptor biomarkers, dose–response fo...
3. Short follow‑up and lack of long‑term safety (nevi/melanoma)Evidence for eruptive nevi, dysplastic lesions and occasional melanomas is driven by case reports/series with short latency and no systematic long‑...Reliance on anecdotal reports, no prospective cohorts, short latency observation windows, inability to assess causality.Mallalieu 2021; Al Abadie et al. 2024; Böhm et al. 2025Prospective longitudinal cohorts and registry linkage studies of users (regulated and unregulated); endpoints: new/changed nevi, biopsy‑confirmed m...
4. Product identity, purity and dosing variability from unregulated marketWidespread online/unregulated sourcing leads to uncertain peptide identity, potency and dosing, undermining safety and attribution.Lack of forensic/analytical characterization of consumer products; heterogeneous user self‑reporting of dose/routes.Al Abadie et al. 2024; Evans et al. (evansUnknownyearauthorsandeditor pages 155-155)Analytical studies of market products (mass spectrometry, potency); cross sectional sampling of online products plus stability/toxicity assays; inf...
5. Cardiovascular and GI safety signals from class analogs (nausea, BP/HR)Frequent nausea and transient BP/HR changes reported in MT‑II and related melanocortin agonist trials/overviews, suggesting systemic autonomic effe...Adverse events under‑reported in small trials; inconsistent BP/HR monitoring and short observation windows.Wessells et al., 2000; Böhm et al. 2025Dedicated safety trials with continuous/ambulatory BP and ECG monitoring, and standardized AE reporting; endpoints: peak BP/HR changes, incidence o...
6. Measurement bias and limited phenotyping in ED/tanning studiesEarly ED/tanning studies used imperfect outcome measures (e.g., single-night NPT, RigiScan) and limited baseline phenotyping, risking confounding.Incomplete baseline characterization, device‑induced artifacts, short assessment periods, subjective endpoints.Wessells et al., 2000; Evans et al. (evansUnknownyearauthorsandeditor pages 155-155)Trials with standardized, validated outcome measures and deep phenotyping (hormones, comorbidities); endpoints: objectively measured efficacy (vali...
7. Mechanistic uncertainty: melanocortin–immune–tumor interactionsPreclinical and case literature raise theoretical risks that potent MC agonists may modulate immune responses affecting melanoma biology, but data ...Sparse mechanistic human data, reliance on in vitro/animal models and speculative links from case reports.Mallalieu 2021; Al Abadie et al. 2024; Böhm et al. 2025Mechanistic translational studies: human tissue/immune profiling, animal models replicating dosing, and controlled biomarker studies; endpoints: im...
8. Public‑health surveillance of use patterns and harmsLiterature documents an underground market and self‑administration with limited population‑level data on prevalence, harms, and user behaviors.Poor epidemiologic data, reliance on qualitative/clinic‑based reports, no systematic surveys or surveillance systems.Callaghan III 2018 cited in overviews (evansUnknownyearauthorsandeditor pages 155-155); Al Abadie et al. 2024Population surveys, sentinel surveillance, and mixed‑methods studies of users and supply chains; endpoints: prevalence, adverse event rates, pathwa...

Systematic Reviews#

Objective. To determine whether systematic reviews, meta-analyses, or comprehensive reviews on Melanotan-2 (MT‑II) exist, and to summarize their conclusions on efficacy and safety.

Evidence base. Dedicated MT‑II systematic reviews/meta-analyses are scarce. However, multiple comprehensive/narrative reviews and a public‑health systematic review include explicit discussion of MT‑II. A 2025 comprehensive review of chronic MC1R activation (JEADV) synthesizes benefits/risks and directly comments on MT‑II’s status and reported effects; a 2007 melanocortin pharmacology review summarizes early MT‑II clinical signals; a 2023 neuroendocrine review covers α‑MSH/MC pathways and cites MT‑II literature; and an IPED injecting systematic review provides public‑health/safety context. Multiple case reports document serious adverse events temporally associated with MT‑II, including melanoma, which underpin safety concerns but do not establish causality.

Efficacy conclusions.

  • Tanning/photoprotection: Reviews concur MT‑II induces skin hyperpigmentation via MC1R; early human pilot data show increased pigmentation after short courses. However, robust randomized evidence for clinical benefits (e.g., photoprotection, chemoprevention) is lacking, and MT‑II is not approved for any indication.
  • Sexual function: Early clinical observations indicate MT‑II can induce penile erection/sexual arousal; subsequent development focused on the metabolite bremelanotide for HSDD. No high‑quality randomized trials establish MT‑II efficacy for erectile dysfunction, and MT‑II itself remains unapproved.
  • Appetite/weight: Animal studies show anorexigenic effects of MT‑II/analogs; human efficacy for weight loss is not established in reviews, and clinical development in obesity focused on other melanocortin agonists rather than MT‑II.

Safety conclusions.

  • Common adverse effects: Nausea, flushing, headache, and erections are repeatedly described with MT‑II in reviews.
  • Serious harms: Case literature reports priapism, rhabdomyolysis, and renal infarction temporally associated with MT‑II. Multiple case reports describe eruptive/atypical nevi and melanomas appearing after MT‑II use; mechanistic links are plausible via MC1R activation, but causality is unproven and may reflect unmasking of pre‑existing lesions. Reviews emphasize uncertainty and caution.
  • Regulatory/quality concerns: MT‑II is not approved for any indication and is commonly sourced online/self‑administered; reviews highlight risks from unregulated products (dose/purity unknown) and advise clinician awareness and patient counseling.

Embedded evidence table of high‑level syntheses:

Reference (first author, year, journal)Article typeScope (how MT-II is covered)Efficacy conclusions (tanning, sexual function, appetite/weight)Safety conclusions (common AEs, serious AEs, cancer risk)Notes / limitations
Böhm M, 2025 (J Eur Acad Dermatol Venereol)Comprehensive narrative reviewOverview of chronic MC1R activation; explicitly discusses MT‑II as a non‑approved, nonselective MCR agonistMT‑II reliably induces hyperpigmentation in short-term studies/pilot data; limited robust clinical trial evidence for therapeutic tanning or other ...Documents frequent acute AEs (nausea, flushing, headache, erections) and numerous case reports (eruptive/atypical naevi, melanoma temporally associ...Narrative synthesis (no pooled meta-analysis); emphasizes mechanistic rationale and case-report safety signals
King SH, 2007 (Curr Top Med Chem)Narrative review / pharmacology reviewMelanocortin receptors as therapeutic targets; discusses MT‑II/PT‑141 physiology and early clinical studiesPhysiologic and small clinical/pilot data show tanning and induction of penile erection/sexual arousal; limited randomized efficacy dataNotes known acute side effects (nausea, erections, flushing); long‑term safety data scarce; raises concerns but no definitive safety synthesisFocused on receptor pharmacology and early clinical evidence (older review)
Wu Q, 2023 (Neuroendocrinology)Narrative review (alpha‑MSH / appetite)Reviews α‑MSH/MC3/4 physiology; cites MT‑II preclinical and some human data as tools to probe appetite circuitsMT‑II/analogs produce anorexigenic effects in animal models; human appetite/weight effects are not established or robustly demonstratedReferences toxicity reports in literature and highlights absence of systematic human safety data for MT‑IIPrimarily mechanistic/appetite focus; not a safety systematic review
Brennan R, 2017 (Health & Social Care in the Community)Systematic review (IPED injecting behaviors)Systematic review of injecting image and performance‑enhancing drugs in general population; includes discussion of melanotropic peptides (e.g., Mel...Not designed to assess clinical efficacy endpoints; documents user claims of improved tanning and sexual effectsHighlights harms associated with injecting IPEDs, health‑service contacts, and public‑health concerns; collates reports of adverse events in usersPopulation/behavioral SR; does not provide pooled clinical efficacy/safety estimates (contextual for MT‑II)
Callaghan DJ, 2018 (Dermatology Online Journal)Market overview / narrativeDescribes underground/commercial market and user reports for Melanotan productsReports widespread user‑reported increased tanning and appearance effects in online reports/forumsSummarizes user‑reported adverse events and regulatory warnings; notes quality/purity concerns for commercially sold productsNon‑systematic market/qualitative overview; based on online sources and user reports

Research Methodology#

  • Early psychogenic ED trial, Journal of Urology (1998): Small double‑blind, placebo‑controlled crossover study in psychogenic ED (n=10). Subcutaneous MT‑II 0.025 mg/kg. Efficacy: 8/10 men had erections; mean tip rigidity ≈38 minutes vs 3 minutes with placebo. Adverse effects: yawning, nausea, decreased appetite; onset latency ~2 hours noted as a limitation. PubMed ID: not reported in the provided evidence.

  • Organic ED study, Urology (2000): Placebo‑controlled injections in men with organic ED (n=10; part of the overall N=20 across the human program). Route: subcutaneous; dose within the range used above. Efficacy: across combined human studies, erections observed in 17/20 without visual sexual stimulation; increased sexual desire reported. Adverse effects: nausea frequent; some severe cases. PubMed ID: not reported in the provided evidence.

  • Dorr et al., Life Sciences (1996): Pilot Phase I clinical study evaluating MT‑II in humans (safety/pharmacology). Specific N, doses, and outcomes are not detailed in the provided excerpts, but this paper is consistently cited as the first human evaluation of MT‑II. PubMed ID: not reported in the provided evidence.

Supporting context and limitations

  • Reviews in men’s health and ED pharmacotherapy summarize these MT‑II human trials and consistently report the erectogenic effect (17/20 subjects overall) alongside frequent nausea and long latency that limited clinical development. These reviews also place MT‑II within the melanocortin agonist class (with bremelanotide/PT‑141 as a later derivative with intranasal delivery), but their MT‑II trial details match the figures above.

Most‑cited studies table (design, N, findings, PMIDs)

Study (first author / journal and source)YearPopulation / ConditionStudy DesignSample Size (N)Dose / RouteKey FindingsAdverse Effects
Wessells et al., International Journal of Impotence Research (human MT-II studies)2000Men with psychogenic and organic EDDouble-blind, placebo-controlled crossover (reviewed human trials)20 (overall across studies)Subcutaneous 0.025–0.157 mg/kg17/20 men had erection after ≥1 MT-II injection; mean ~41 min tip rigidity; increased sexual desireCommon: nausea, yawning; some severe nausea at higher doses
Psychogenic ED study (J Urol 1998; likely reported in reviews)1998Men with psychogenic EDSmall double-blind, placebo-controlled crossover (reported in reviews)10Subcutaneous 0.025 mg/kg8/10 men had erections; mean tip rigidity ~38 min vs 3 min with placeboYawning, nausea, decreased appetite
Urology 2000 (organic ED study)2000Men with organic EDPlacebo-controlled injections (reported in reviews)10 (part of combined N=20 across studies)Subcutaneous injections (dose not fully detailed beyond studies above)Across combined studies 17/20 men had erection without visual stimulation; increased sexual desire reportedNausea common
Dorr et al., Life Sciences — pilot Phase I evaluation of MT-II1996Healthy volunteers / early human subjectsPilot Phase I clinical study (safety/pharmacology)not reported in current contextnot reported in current contextSafety/pharmacology evaluated in pilot Phase I (details not specified in current context)Safety/tolerability assessed (specific AEs not reported in current context)

Transparency note on PubMed IDs

PubMed IDs for the cited primary human Melanotan‑2 (MT‑II) clinical studies could not be located in the tool-provided evidence, so PMIDs are not reported here. Study details in the answer (design, sample size, key findings) are taken from peer‑reviewed reviews and the IJIR 2000 report; where the evidence included DOIs these are noted, but primary-article PubMed identifiers were not available in the provided context.

Blockquote: A brief transparent note that PubMed identifiers were not present in the retrieved evidence and that study details were taken from review-derived summaries and available DOIs; this clarifies a key limitation of the data used.

Evidence Quality Assessment#

The evidence base for Melanotan-2 currently consists primarily of preclinical studies. On the evidence hierarchy:

  • Systematic reviews/meta-analyses: Limited availability
  • Randomized controlled trials (human): Not completed
  • Animal studies: Extensive body of research
  • In vitro studies: Multiple cell culture experiments
  • Case reports: Limited anecdotal evidence

Where to Find Melanotan-2

Research-grade suppliers verified by our scoring methodology.

Great Northern Peptides8/10
International
Biotech Peptides7.7/10
US Domestic
Particle Peptides7.7/10
International
Verified Peptides7.6/10
US Domestic
Sports Technology Labs7.5/10
US Domestic
Core Peptides7.4/10
US Domestic

View all 31 vendors →

Frequently Asked Questions About Melanotan-2

Explore Further

Calculate your dose

Reconstitution volumes, injection doses, and supply planning

Explore the evidence

Filter and sort clinical studies across all peptides

⚠️

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.

CompareToolsVendors